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Neoadjuvant chemotherapy (NAC) is widely used in locally advanced breast cancer (BC) treatment. The role of postmastectomy
radiotherapy (PMRT) after NAC is strongly debated. The aim of our analysis was to identify major prognostic factors in a single-
center series, with emphasis on PMRT. From 1997 to 2011, 170 patients were treatedwithNACandmastectomy at our center; 98 cases
(57.6%) underwent PMRT and 72 cases (42.4%) did not receive radiation. At a median follow-up period of 7.7 years (range 2–16) for
thewhole cohort,median time to locoregional recurrence (LRR)was 3.3 years (range 0.7–12.4).The 5-year and 10-year actuarial LRR
rate were 14.5% and 15.9%, respectively. At the multivariate analysis the factors that significantly correlated with survival outcome
were ≥4 positive nodes (HR 5.0, 1.51–16.52; 𝑃 = 0.035), extracapsular extension (HR 2.18, 1.37–3.46; 𝑃 = 0.009), and estrogen
receptor positive disease (HR 0.57, 0.36–0.90; 𝑃 = 0.003). Concerning LRR according to use of radiation, PMRT reduced LRR
for patient with clinical T3 staged disease (𝑃 = 0.015). Our experience confirmed the impact of pathological nodal involvement
on survival outcome. PMRT was found to improve local control in patients presenting with clinical T3 tumors, regardless of the
response to chemotherapy.
1. Introduction
Neoadjuvant chemotherapy (NAC) is widely used in locally
advanced breast cancer (BC) treatment. It is increasingly used
in women with early stage disease [1]. It allows the clinicians
to observe tumor response andmodify radiotherapy plan [2].
Adjuvant therapeutic strategies for patients who underwent
NAC do not differ substantially from patients treated with
upfront surgery [3–6]; nevertheless, the role of postmastec-
tomy radiotherapy (PMRT) after NAC is strongly debated.
Moreover there is a lack of prospective trials in this treatment
setting.
In an era of “tailored treatment,” additional data are
needed for patients who receive this treatment sequence
to determine which subsets of patients can benefit from
radiation [7].
The aim of our analysis was to identify major prognostic
factors in a single-center series of advanced BC patients
receiving NAC, with emphasis on the role of PMRT.
2. Materials and Methods
2.1. Patient Population. From 1997 to 2011, 226 patients were
treated with NAC and mastectomy at the University of
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Florence Radiotherapy Unit (Florence, Italy). Previous solid
tumors, age less than 18, and BC recurrences or contralateral
tumor were considered exclusion criteria of the study. To
minimize bias, all patients with disease recurrence within 2
months after surgery, completion of adjuvant chemotherapy,
and aminimum follow-up period shorter than 6monthswere
excluded from analysis. We retrospectively reviewed a series
of 170 BC patients who received NAC and mastectomy; 98
cases (57.6%) underwent PMRT and 72 cases (42.4%) did not
receive radiation. Informed consent was obtained from all
patients.
In ourmultidisciplinary team, specialized expert patholo-
gists, dedicated to BC specimens’ evaluation, perform pathol-
ogy assessment. Estrogen receptor (ER) status, progesterone
receptor (PgR) status, and Ki-67 labeling index determined
with the MIB1 monoclonal antibody were assessed. For
ER and PgR status two categories (negative/positive) were
considered according to well-established cut-off values [8].
HER2 immunohistochemistry (IHC) scores of 0 and 1+ were
considered negative. HER2 IHC 3+ and fluorescent in situ
hybridization (FISH)—amplified tumors, were considered
positive. All IHC2+ tumorswere tested for gene amplification
by FISH. The applied well-validated [9] primary antibodies
for evaluating ER and PgR in BC by IHC have been exten-
sively described in earlier published reports [10, 11].
BC was classified according to the histological type and
the AJCC TNM classification of malignant tumors. Concern-
ing Ki-67, we used a validated [12] cut-off value of 20% to
distinguish Ki-67 high from Ki-67 low, although the ideal
threshold has not been identified yet and varies widely from
1 to 28.6% [13].
2.2. Treatment Details. All patients, except 8 cases, received
anthracyclines as part of a combination chemotherapy regi-
men (98.8%),with 69 patients (40.6%) also receiving a taxane.
Concerning HER2 status, 23 patients had HER2 positive and
45 patients had HER2 negative status at pathological speci-
men; in 102 cases HER2 status was undetermined or missing.
None of these patients were treated with neoadjuvant or
adjuvant trastuzumab, since they were treated before 2006.
Most commonly administered chemotherapy regimens
were FEC and ET; FEC chemotherapy consisted of 500mg/
m2 5-fluorouracil, 75mg/m2 epirubicin, and 500mg/m2
cyclophosphamide, given on day 1.The ET regimen consisted
of 75mg/m2 epirubicin and 75mg/m2 docetaxel, given on day
1. The median number of chemotherapy cycles received was
4 (mean, 4.7; range, 2–6).
Additionally, 108 patients (88.2%) received adjuvant
hormonal therapy: tamoxifen for 5 years (𝑛 = 63; 37.1%),
aromatase inhibitors for 5 years (𝑛 = 52; 30.6%), and
tamoxifen for 2 years and then shift to aromatase inhibitors
(𝑛 = 35; 20.5%).
Concerning PMRT, the treatment volumes typically
included the chest wall and draining lymphatics (𝑛 = 84;
85.7%), consisting in the supraclavicular (SCV) and infra-
clavicular (ICV) nodal region (total dose 50Gy; 2Gy daily
fractions), with mixed photon and electron beams technique,
chosen at physician discretion. In our Institute we did not
irradiate mammary internal nodal region, unless patholog-
ically involved. In selected cases (𝑛 = 14; 14.3%) only chest
wall was irradiated.
Patients underwent a treatment-planning noncontrast
CT scan. Concerning CTV identification, for chest wall vol-
ume, the cranial limit was the caudal border of the clavicular
head, the caudal limit was the contralateral inframammary
fold, the lateral limit was the midaxillary line, and the medial
limit was the sterna-rib junction. For SCV nodes the cranial
limit was a line passing below the cricoid cartilage, the
caudal limit was the caudal edge of the clavicular head, the
anterior limit was the poster edge of the sternocleidomastoid
(SCM) muscle, the posterior limit was the anterior aspect of
the scalene muscle, the lateral limit was the lateral edge of
the SCM muscle cranially, and the junction first rib-clavicle
caudally, and the medial limit was a line excluding thyroid
and trachea. For ICV nodes, the cranial limit was pectoralis
minormuscle insert on coracoid, the caudal limit was axillary
vessels cross-medial edge of pectoralis minor muscle, the
anterior limit was the posterior surface of pectoralis major
muscle, the posterior limit was ribs and intercostal muscles,
the lateral limit was the medial border of pectoralis minor
muscle, and the medial limit was the thoracic inlet.
2.3. Statistical Analysis. For the survival analysis, the date of
histological BC diagnosis was used as the start of observation.
The survival time was calculated from the date of diagnosis
to the date of death or the date of the last follow-up for
living patients. We considered as events the deaths for all
causes (overall survival, OS). We also estimated the disease-
free survival (DFS) as the interval time from the date of
diagnosis to the date of locoregional recurrence (LRR) or
distant metastases (DM).
The actuarial rates of death, LRR, or DM were calculated
according to the Kaplan-Meier method, and comparisons
were made using the log-rank test. Estimated relative risk of
death, LRR, or DMwere expressed as hazard ratios (HR) and
their corresponding 95% confidence intervals (95% CI).
The clinical and pathologic factors that were statistically
significant (two-tailed 𝑃 < 0.05) on univariate analysis of
LRR, DM, or OS were included in a multivariate analysis
using the Cox proportional hazards regression model. All
statistical tests were performed by the SAS software (SAS for
Windows, version 9.1).
In order to analyze if the concomitant presence of well-
known [14] risk factors influences the LRR rate, we strati-
fied the patients in three risk groups (0-1 factors versus 2
factors versus 3–5 factors). We considered the following risk
features: skin/nipple involvement, SCV nodal involvement,
no tamoxifen use, extracapsular extension (ECE), and ER
negative disease.
3. Results
3.1. Series Characteristics. The median age at BC diagnosis
was 48.9 years (range 24–76). The median follow-up periods
of all irradiated and nonirradiated cases were 7.2 and 6.7
years, respectively.
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Table 1 showed major clinical characteristics of the whole
series and stratified by radiation treatment. When compared
with patients who did not receive PMRT, a larger number
of irradiated patients had greater clinical and pathological
T, N, and combined AJCC TNM stage (𝑃 ≤ 0.024 for
all comparisons). There were no differences between the
two groups considering age, histology, nuclear grade, lymph
vascular invasion (LVI), downstaging after NAC based on
pathological response, use of hormonal therapy, Ki-67 index,
and percentage of ER and PgR.
3.2. Prognostic Factors of the Whole Series. At a median
follow-up period of 7.7 years (range 2–16; standard deviation
(SD) 5.1), 98 patients are alive (57.6%) and 72 patients are dead
(42.4%). Median time to LRR (𝑛 = 26) was 3.3 years (range
0.7–14.6; SD 3.9); median time to DM (𝑛 = 86) was 3.0 years
(range 0.7–12.4; SD 2.6).The 5-year and 10-year actuarial LRR
rate were 14.5% and 15.9%, respectively.
The majority of LRR failures occurred on the chest wall
(𝑛 = 15; 57.7%). SCV was the first nodal site of relapse in 7
cases (26.9%). Axillary (𝑛 = 2), infraclavicular (𝑛 = 1), and
internal mammary nodal regions (𝑛 = 1) were rare sites of
LRR (15.4%).
Table 2 showed LRR,DM, andOS rates according tomain
clinical features. In Table 3 survival rates were summarized
according to major pathologic characteristics.
The factors that significantly correlated with poor LRR
outcome were clinical N2 tumors, pathologic skin involve-
ment, LVI, and the presence of ECE. The factors that signif-
icantly correlated with poor DM outcome were clinical N2
tumors, pN2, pN3 tumors, LVI, and ECE. Concerning OS,
the significant protective features were pT1 tumors and ER
positive status, while pN1, pN2, pN3 tumors, and ECE were
unfavorable risk factors.
In the multivariate Cox regression analysis no factors
were independently associated with LRR. The multivariate
analysis of distant metastases occurrence and overall survival
are described in Table 4. The factors that significantly corre-
latedwith survival outcomewere≥4 positive nodes, ECE, and
estrogen receptor positive disease.
The LRR rate for the 61 patients (35.9%) with one or
none of selected [14] risk factors (6 events) was 10.9%, the
75 patients (44.1%) with two factors (10 events) had a rate of
24.5%, and the 34 patients (20%) with three or more factors
(10 events) had a rate of 54.3% (log rank test 𝑃 = 0.023;
Figure 1). In an analysis stratified by radiation use, PMRT
showed a protective effect (𝑃 = 0.029).
3.3. Locoregional Recurrence Rate according to Use of Post-
mastectomy Radiotherapy. In Table 5 the impact of PMRT on
LRR for various subgroups of patients is shown.
PMRT was associated with reduced LRR for patient with
clinical T3 staged disease (16.7% versus 38.7%; 𝑃 = 0.015;
Figure 2). For patients with clinical T4 and clinical N2 and
N3 tumors, no difference in LRR rates was observed. Also
concerning pathological features, no difference in LRR rates
was observed. In addition, in the subset of patients that
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Figure 1: Locoregional recurrence rates according to number of
selected risk factors.
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Figure 2: Kaplan-Meier survival curve of locoregional recurrence
for the cohort of patients with clinically T3 disease who received
NAC and mastectomy. Patients were stratified by whether they
received postmastectomy radiation (PMRT; 𝑛 = 21) or not (No
PMRT; 𝑛 = 27). Statistical comparison between the survival curves
was made using the log-rank test (𝑃 = 0.015).
achieved complete response after NAC (pCR; 𝑃 = 0.29)
or downstaging (𝑃 = 0.68), no statistical significance was
evidenced.
3.4. Treatment Safety. Major hematological and nonhema-
tological side effects are summarized in Table 6. The most
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Table 1: Distribution of 170 breast cancer cases according to adjuvant radiotherapy.
Feature Total
𝑛 = 170
No PMRT
𝑛 = 72
PMRT
𝑛 = 98
𝑃 value∘
Age groups
≤40 33 18 15
41–50 62 25 37
51–60 5 18 32
>60 25 11 14 0.40
Clinical T classification
T1 4 2 2
T2 52 28 24
T3 48 27 21
T4 66 15 51 0.002
Clinical N classification
N0 42 20 22
N1 95 45 50
N2 33 7 25 0.024
Clinical stage
IIA 16 8 8
IIB 51 32 19
IIIA 35 17 18
IIIB 63 15 48
IIIC 3 — 5 0.0001
Multiple Foci
No 99 50 49
Yes 71 2 49 0.012
Pathologic T classification
pTx/pTis 14 7 7
pT1 26 13 13
pT2 75 39 36
pT3 18 7 11
pT4 37 6 31 0.007
Pathologic N classification
pN0 20 14 6
pN1 63 29 34
pN2 52 16 36
pN3 35 13 22 0.02
Downstage
No 115 43 72
Yes 55 29 26 0.07
Histology
Ductal invasive 118 55 63
Lobular invasive 36 12 24
Others 16 5 11 0.24
Pathologic skin involvement
Absent 136 66 70
Present 34 6 28 0.001
Extracapsular extension
Absent 115 52 63
Present 55 20 35 0.32
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Table 1: Continued.
Feature Total
𝑛 = 170
No PMRT
𝑛 = 72
PMRT
𝑛 = 98
𝑃 value∘
LVI
Absent 101 47 54
Present 69 25 44 0.21
Nuclear grading∗
G1 11 6 5
G2 54 26 28
G3 80 33 47 0.58
Ki 67 index
<20 117 53 64
≥20 53 19 34 0.32
ER status
Negative 64 30 34
Positive 106 42 64 0.42
PgR status
Negative 83 40 43
Positive 87 32 55 0.16
NAC regimen
Anthracyclines-based 69 27 42
Anthracyclines and taxanes-based 93 44 49
No anthracyclines 8 1 7 0.13
Adjuvant hormonal therapy
No 62 28 34
Tamoxifen 75 31 44
AIs 33 13 20 0.89
∗Some data are missing; ∘𝑃 value from Fisher exact test or chi-square for trend, as appropriate.
PMRT: postmastectomy radiotherapy; LVI: lymphovascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC: neoadjuvant chemotherapy;
AIs: aromatase inhibitors.
represented hematological G3–G5 side effect was neutrope-
nia (17%). The most frequent radiotherapy-related acute side
effect was erythema (33%). At amedian follow-up of 7.2 years,
the most represented late RT-related side effect was fibrosis
(20%).
4. Discussion
The Danish and the British Columbia trials have established
the survival advantage following radiotherapy in postmas-
tectomy patients [15, 16]. The Early Breast Cancer Trialists’
Collaborative Group meta-analysis has demonstrated that
PMRT, besides improving local control rates, confers an OS
benefit [17]. On the basis of these studies and others, the role
of the indication to PMRT has traditionally been determined
by pathologic staging, with surgery as the first treatment
modality [18, 19].
NAC is nowadays based on regimens containing anthra-
cyclines, taxanes, and trastuzumab in case of HER2 pos-
itive disease. The toxicity profile of these drugs is well
known, namely, characterized by potential cardiac [20–23]
and pulmonary [24–26] adverse events. Although NAC has
many advantages, its impact on surgical staging reduces
the applicability of the traditional pathologic guidelines for
PMRT.
Guidelines for the use of PMRT after NAC have not
been established. Retrospective series have demonstrated that
the omission of PMRT after NAC in high-risk patients can
result in an unacceptable high rate of LRR, even in case of
pathological complete response [7, 27]. For this reason, the
role of PMRT is generally determined by clinical staging
before NAC without regard for the response to NAC [18].
Risk factors for LRR in this specific setting are not well
established. Advanced clinical or pathologic stage, triple-
negative receptor status, and presence of LVI and/or ECE
emerged as high-risk features that should warrant consid-
eration of PMRT after NAC [28]. In our experience greater
clinical nodal status, tumor stage, the presence of LVI, and
nodal ECE emerged as adverse prognostic factors; these
results are in line with many published series [7, 18, 28, 29].
Concerning age at diagnosis, Garg et al. [30] retrospec-
tively analyzed 107 consecutive BC patients younger than 35
years with stage IIA–IIIC disease, treated with doxorubicin-
based NAC and mastectomy, with or without PMRT. In this
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Table 2: Locoregional recurrence, distant metastases, and overall survival rates according to clinical factors.
Variable Patient Overall survival LRR free survival DM free survival
Deaths 𝑃 value LRR 𝑃 value DM 𝑃 value
Age groups
≤40 33 16 6 20
41–50 62 24 9 20
51–60 5 20 9 25
>60 25 12 0.73 2 0.74 13 0.67
Clinical T
T1 4 3 0 3
T2 52 15 3 18
T3 48 17 9 25
T4 66 37 0.09 14 0.28 40 0.12
Clinical N
N0 42 14 5 15
N1 95 39 11 49
N2 33 19 0.15 10 0.034 22 0.028
Clinical stage
IIA 16 5 0 5
IIB 51 17 6 21
IIIA 35 13 6 20
IIIB 63 36 14 39
IIIC 3 1 0.15 0 0.19 1 0.09
Multiple Foci
No 99 40 18 46
Yes 71 32 0.60 8 0.28 40 0.19
Downstage
No 115 50 19 64
Yes 55 22 0.34 7 0.31 22 0.029
PMRT
No 72 31 12 36
Yes 98 41 0.83 14 0.57 50 0.93
PMRT volumes
Chest wall 14 5 1 5
Chest wall + SC 74 34 0.35 12 0.38 43 0.11
NAC regimen
Anthracyclines-based 69 35 14 41
Anthracyclines- and taxanes-based 93 33 10 41
No anthracyclines 8 4 0.25 2 0.29 4 0.16
Adjuvant hormonal therapy
No 62 34 10 35
Tamoxifen 75 28 11 34
AIs 33 10 0.11 5 0.93 17 0.31
Total 170 72 26 86
LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; NAC: neoadjuvant chemotherapy; SC: supraclavicular nodal
region; AIs: aromatase inhibitors.
experience the use of PMRT led to a statistically greater rate of
local control and OS compared with patients without PMRT.
Response to NAC is another debated issue in adjuvant
PMRTdecision-making.Data regarding LRR rates in patients
who achieve a pCR are limited, although few data supported
stage IIIA patients with pCR as being at low risk [28]. Con-
cerning tumor biology and chemotherapy response, many
experiences showed that residual disease after NAC seems to
have a greater implication for outcome for those in whom
systemic therapy would have been expected to produce a
more favorable response, such as ER and HER2 positive
patients [31–34].
Conversely, other studies suggested how PMRT should
be indicated regardless of response to NAC [18, 35]. Also in
BioMed Research International 7
Table 3: Locoregional recurrence, distant metastases, and overall survival rates according to pathologic factors.
Variable Patient Overall survival LRR free survival DM free survival
Deaths 𝑃 value LRR 𝑃 value DM 𝑃 value
Multiple foci
No 99 40 18 46
Yes 71 32 0.60 8 0.28 40 0.19
Pathologic T
pTx/pTis 14 8 3 8
pT1 26 5 0 7
pT2 75 29 8 38
pT3 18 10 5 11
pT4 37 20 0.04 10 0.015 22 0.13
Pathologic N
pN0 20 3 2 3
pN1 63 27 9 28
pN2 52 26 12 33
pN3 35 16 0.026 3 0.12 22 0.0002
Stage
0 3 2 1 2
I 6 0 0 0
IIa 25 7 3 7
IIb 25 9 4 9
IIIa 43 20 6 27
IIIb 39 18 8 21
IIIc 29 16 0.049 4 0.76 20 0.0006
Histology
Ductal invasive 118 52 19 59
Lobular invasive 36 13 1 19
Others 16 7 0.85 6 0.008 8 0.94
Pathologic skin involvement
Absent 136 56 16 67
Present 34 16 0.78 10 0.018 19 0.83
LVI
Absent 101 38 14 44
Present 69 34 0.19 12 0.35 42 0.044
Nuclear grading∗
G1 11 4 0 5
G2 54 17 3 25
G3 80 40 0.18 16 0.024 44 0.52
Ki 67 index
<20 117 48 21 57
≥20 53 24 0.15 5 0.34 29 0.09
ER status
Negative 64 35 10 37
Positive 106 37 0.015 16 0.99 49 0.20
PgR status
Negative 83 36 13 41
Positive 87 36 0.83 13 0.87 45 0.83
Extracapsular extension
Absence 115 37 13 48
Presence 55 35 0.0007 13 0.035 38 0.003
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Table 3: Continued.
Variable Patient Overall survival LRR free survival DM free survival
Deaths 𝑃 value LRR 𝑃 value DM 𝑃 value
Total 170 72 26 86
∗Some data are missing.
LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR:
progesterone receptors.
Table 4: Multivariate analysis of distant metastases occurrence and overall survival.
Factor Hazard ratio 95% confidence interval 𝑃 value
Distant metastases
pN2 6.95 2.11–22.56 0.007
pN3 7.21 2.15–24.18 0.009
Extracapsular extension 1.91 1.25–2.92 0.023
Overall survival
pN2 5.00 1.51–16.52 0.035
pN3 4.50 1.31–15.48 0.037
Extracapsular extension 2.18 1.37–3.46 0.009
Estrogen receptor positive disease 0.57 0.36–0.90 0.003
our series disease downstaging and/or pCR to NAC were not
independent prognostic factors for LRR occurrence.
In our experience PMRTwas significantly protective only
in case of clinical staged T3 tumors, regardless of response to
NAC. Our results are consistent with the experience of M. D.
Anderson Cancer Center, which in our knowledge represents
the largest published series.
In a relevant study published in 2004, Huang et al. [7]
showed how radiation was found to benefit both local control
and survival for patients presentingwith clinical T3 tumors or
stage III-IV disease (ipsilateral SCV nodal) and for patients
with four or more positive nodes.
In 2011, Nagar et al. [36] tried to determine the impact of
PMRT after NAC on LRR in 162 patients with clinical T3N0
disease. PMRT was effective in reducing the LRR rate, even
when there was no pathologic evidence of nodal involvement
after NAC.
However we are aware of the limitations of our retrospec-
tive study: the two cohorts in the analyses had differences in
several factors, and the more advanced tumor characteristics
were in the PMRT group. PMRT may overcome negative
pathologic features in the cohort.
A complex evaluation based on the presence of multiple
risk factors should be of primary importance in the decision-
making process for PMRT after NAC.
Fowble et al. [28] identified a cohort of women treated
with NAC andmastectomy for whom PMRTmay be omitted
according to the projected risk of LRR. Seven breast cancer
physicians from the University of California cancer centers
created 14 hypothetical clinical case scenarios; an overall
summary risk assessment table was developed, using the
American College of Radiology rating scale. Clinical stage
II (T1-2N0-1) patients, aged > 40 years, with ER positive
subtype, with pCR or 0–3 positive nodes without LVI or ECE,
were identified as having <10% risk of LRRwithout radiation.
Huang et al. [7, 14] retrospectively reviewed the hospital
records of 542 patients treated on six consecutive institutional
prospective trials using NAC and PMRT. In the multivariate
analysis, skin/nipple involvement, SCV nodal involvement,
no tamoxifen use, ECE, and ER negative were independently
associated with developing LRR (HR 2.1–2.8; 𝑃 < 0.001–
0.020). The 10-year rate of LRR for patients with one or none
of these factors was only 4%, but patients with two factors
had a rate of 8%, and patients with three or more factors
had a rate of 28% (𝑃 < 0.0001 for 0-1 factor versus 3–5
factors).
In order to validate the independent factors shown in
the experience of the M. D. Anderson Cancer Center, we
performed the same multiple factors analysis. Also in our
series we found a significant higher LRR rate in patients
with a greater number of risk factors (HR 2.70; 95% CI
1.12–6.53; 𝑃 = 0.023; 54.3% LRR rate for patients with 3–5
factors).
The 2007 National Cancer Institute conference report
recommended PMRT after NAC for patients presenting with
clinical stage III disease or those with positive nodes after
chemotherapy [37]. Our experience adds strength to the
experiences that suggest PMRT after NAC based on clinical
staging; however, we strongly believe that PMRT after NAC
should be indicated following a comprehensive assessment of
multiple factors.
5. Conclusions
Our experience confirmed the impact of pathological nodal
involvement in patients’ outcome. After NAC and mastec-
tomy, PMRT was found to benefit local control of patients
presenting with clinical T3 tumors, regardless of the response
to chemotherapy. Radiation should always be considered after
a carefulmultidisciplinary assessment ofmultiple risk factors.
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Table 5: Locoregional recurrence-free survival rate according to postmastectomy radiotherapy.
Feature 𝑁 No PMRT PMRT LRR 𝑃 value
No PMRT PMRT
Age groups
≤40 33 18 15 5 1 0.13
41–50 62 25 37 4 5 0.53
51–60 5 18 32 3 6 0.62
>60 25 11 14 0 2 0.24
Clinical T
T1 4 2 2 0 0 —
T2 52 26 24 3 0 0.12
T3 48 27 21 8 1 0.015
T4 66 15 51 1 13 0.15
Clinical N
N0 42 20 22 3 2 0.64
N1 95 45 90 7 4 0.15
N2 33 7 26 2 8 0.87
Multiple foci
No 99 50 49 1 7 0.27
Yes 71 22 49 1 7 0.26
Pathologic T
pTx/pTis 14 7 7 2 1 0.29
pT1 26 13 13 0 0 —
pT2 75 39 36 6 3 0.10
pT3 18 7 11 3 2 0.18
pT4 37 6 31 1 9 0.49
Pathologic N
pN0 20 14 6 2 0 0.35
pN1 63 29 34 3 6 0.62
pN2 52 16 36 5 7 0.16
pN3 35 13 22 2 1 0.54
Downstage
No 115 43 72 8 11 0.51
Yes 55 29 26 4 3 0.68
Histology
Ductal invasive 118 55 63 9 10 0.78
Lobular invasive 36 12 24 0 1 0.48
Others 16 5 11 3 3 0.17
Pathologic skin involvement
Absent 136 66 70 11 5 0.061
Present 34 6 28 1 9 0.44
LVI
Absent 101 47 54 8 6 0.32
Present 69 25 44 4 8 0.93
Nuclear grading∗
G1 11 6 5 0 0 —
G2 54 26 28 3 0 0.06
G3 80 33 47 7 9 0.86
Ki 67 index
<20 117 53 64 10 11 0.76
≥20 53 19 34 2 3 0.69
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Table 5: Continued.
Feature 𝑁 No PMRT PMRT LRR 𝑃 value
No PMRT PMRT
ER status
Negative 64 30 34 4 6 0.81
Positive 106 42 64 8 8 0.32
PgR status
Negative 83 40 43 6 7 0.93
Positive 87 32 65 6 7 0.39
Extracapsular extension
Absence 115 52 63 8 5 0.20
Presence 55 20 35 4 9 0.89
NAC regimen
Anthracyclines-based 69 27 42 5 9 0.74
Anthracyclines- and taxanes-based 93 44 49 6 4 0.38
No anthracyclines-based 8 1 7 1 1 0.008
Adjuvant hormonal therapy
No 62 28 34 4 6 0.86
Tamoxifen 75 31 44 5 6 0.71
AIs 33 13 20 3 2 0.32
Total 170 72 98 12 14
∗Some data are missing.
LRR: locoregional recurrence; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC:
neoadjuvant chemotherapy; AIs: aromatase inhibitors.
Table 6: Main chemotherapy- and radiotherapy-related adverse
events.
𝑁 %
Chemotherapy-related side effects
Anemia
Grades 0–2 150 88
Grades 3–5 20 12
Neutropenia
Grades 0–2 142 83
Grades 3–5 28 17
Piastrinopenia
Grades 0–2 150 88
Grades 3–5 20 20
Mucositis
Grades 0–2 158 93
Grades 3–5 12 7
Alopecia 162 95
Hypertransaminasemia 15 9
Febrile neutropenia 5 3
𝑅𝑎𝑑𝑖𝑜𝑡ℎ𝑒𝑟𝑎𝑝𝑦-𝑟𝑒𝑙𝑎𝑡𝑒𝑑 𝑠𝑖𝑑𝑒 𝑒𝑓𝑓𝑒𝑐𝑡𝑠∘
Erythema 32 33
Thoracic wall pain 25 25
Edema 3 3
Fatigue 30 30
Fibrosis 20 20
Telangiectasia 8 8
∘PMRT group, any grades.
However prospective trials in properly selected patients are
strongly needed.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
All the authors contributed equally to this paper.
References
[1] J. S. D. Mieog, J. A. van der Hage, and C. J. H. van de Velde,
“Neoadjuvant chemotherapy for operable breast cancer,” The
British Journal of Surgery, vol. 94, no. 10, pp. 1189–1200, 2007.
[2] K. E. Hoffman, E. A. Mittendorf, and T. A. Buchholz, “Opti-
mising radiation treatment decisions for patients who receive
neoadjuvant chemotherapy andmastectomy,”TheLancetOncol-
ogy, vol. 13, no. 6, pp. e270–e276, 2012.
[3] M. E. Taylor, B. G. Haffty, R. Rabinovitch et al., “ACR appro-
priateness criteria on postmastectomy radiotherapy expert
panel on radiation oncology-breast,” International Journal of
Radiation Oncology Biology Physics, vol. 73, no. 4, pp. 997–1002,
2009.
[4] A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B.
Thu¨rlimann, and H.-J. Senn, “Thresholds for therapies: high-
lights of the St gallen international expert consensus on the pri-
mary therapy of early breast cancer 2009,” Annals of Oncology,
vol. 20, no. 8, pp. 1319–1329, 2009.
[5] R.W.Carlson,D. C. Allred, B.O.Anderson et al., “Breast cancer.
Clinical practice guidelines in oncology,” Journal of the National
Comprehensive Cancer Network, vol. 7, no. 2, pp. 122–192, 2009.
BioMed Research International 11
[6] National Institute for Health Clinical Excellence, Early and
Advanced Breast Cancer: Diagnosis and Treatment, NICE Clin-
ical Guideline no. 80, NICE, London, UK, 2009.
[7] E. H. Huang, S. L. Tucker, E. A. Strom et al., “Postmastectomy
radiation improves local-regional control and survival for
selected patients with locally advanced breast cancer treated
with neoadjuvant chemotherapy and mastectomy,” Journal of
Clinical Oncology, vol. 22, no. 23, pp. 4691–4699, 2004.
[8] N. Bouzubar, K. J. Walker, K. Griffiths et al., “Ki67 immunos-
taining in primary breast cancer: pathological and clinical
associations,” The British Journal of Cancer, vol. 59, no. 6, pp.
943–947, 1989.
[9] M. E.H.Hammond,D. F. Hayes, A. C.Wolff, P. B.Mangu, and S.
Temin, “American society of clinical oncology/college of Amer-
ican pathologists guideline recommendations for immunohis-
tochemical testing of estrogen and progesterone receptors in
breast cancer,” Journal of Oncology Practice, vol. 6, no. 4, pp. 195–
197, 2010.
[10] I. Meattini, L. Livi, C. Saieva et al., “Prognostic role of human
epidermal growth factor receptor 2 status in premenopausal
early breast cancer treated with adjuvant tamoxifen,” Clinical
Breast Cancer, vol. 13, no. 4, pp. 247–253, 2013.
[11] L. Livi, I. Meattini, C. Saieva et al., “Prognostic value of positive
human epidermal growth factor receptor 2 status and negative
hormone status in patients with T1a/T1b, lymph node-negative
breast cancer,” Cancer, vol. 118, no. 13, pp. 3236–3243, 2012.
[12] E. Munzone, E. Botteri, A. Sciandivasci et al., “Prognostic value
of Ki-67 labeling index in patients with node-negative, triple-
negative breast cancer,” Breast Cancer Research and Treatment,
vol. 134, no. 1, pp. 277–282, 2012.
[13] M. Dowsett, T. O. Nielsen, R. A'Hern et al., “Assessment of Ki67
in breast cancer: recommendations from the International Ki67
in breast cancer working group,” Journal of the National Cancer
Institute, vol. 103, no. 22, pp. 1656–1664, 2011.
[14] E. H. Huang, S. L. Tucker, E. A. Strom et al., “Predictors of
locoregional recurrence in patients with locally advanced breast
cancer treated with neoadjuvant chemotherapy, mastectomy,
and radiotherapy,” International Journal of Radiation Oncology
Biology Physics, vol. 62, no. 2, pp. 351–357, 2005.
[15] M. Overgaard, P. S. Hansen, J. Overgaard et al., “Postoperative
radiotherapy in high-risk premenopausal women with breast
cancer who receive adjuvant chemotherapy,” The New England
Journal of Medicine, vol. 337, no. 14, pp. 949–955, 1997.
[16] J. Ragaz, S. M. Jackson, N. Le et al., “Adjuvant radiotherapy and
chemotherapy in node-positive premenopausal women with
breast cancer,” The New England Journal of Medicine, vol. 337,
no. 14, pp. 956–962, 1997.
[17] P. M. P. Poortmans, J. L. M. Venselaar, H. Struikmans et al., “
The potential impact of treatment variations on the results of
radiotherapy of the internal mammary lymph node chain: a
quality-assurance report on the dummy run of EORTC phase
III randomized trial 22922/10925 in stage I—III breast cancer,”
International Journal of Radiation Oncology Biology Physics, vol.
49, no. 5, pp. 1399–1408, 2001.
[18] J. L. Wright, C. Takita, I. M. Reis et al., “Predictors of locore-
gional outcome in patients receiving neoadjuvant therapy and
postmastectomy radiation,” Cancer, vol. 119, no. 1, pp. 16–25,
2013.
[19] L. Livi, C. Saieva, B. Detti et al., “Loco-regional recurrence
in 2064 patients with breast cancer treated with mastectomy
without adjuvant radiotherapy,” European Journal of Surgical
Oncology, vol. 33, no. 8, pp. 977–981, 2007.
[20] E. A. Perez, V. J. Suman, N. E. Davidson et al., “Effect of
doxorubicin plus cyclophosphamide on left ventricular ejection
fraction in patients with breast cancer in the north central can-
cer treatment group N9831 intergroup adjuvant trial,” Journal of
Clinical Oncology, vol. 22, no. 18, pp. 3700–3704, 2004.
[21] E. Tan-Chiu, G. Yothers, E. Romond et al., “Assessment of car-
diac dysfunction in a randomized trial comparing doxorubicin
and cyclophosphamide followed by paclitaxel, with or without
trastuzumab as adjuvant therapy in node-positive, human epi-
dermal growth factor receptor 2-overexpressing breast cancer:
NSABP B-31,” Journal of Clinical Oncology, vol. 23, no. 31, pp.
7811–7819, 2005.
[22] M. S. Ewer and J. A. O'Shaughnessy, “Cardiac toxicity of
trastuzumab-related regimens in HER2-overexpressing breast
cancer,” Clinical Breast Cancer, vol. 7, no. 8, pp. 600–607, 2007.
[23] M. L. Telli, S. A. Hunt, R. W. Carlson, and A. E. Guardino,
“Trastuzumab-related cardiotoxicity: calling into question the
concept of reversibility,” Journal of Clinical Oncology, vol. 25, no.
23, pp. 3525–3533, 2007.
[24] M. J. Piccart, J. Klijn, R. Paridaens et al., “Corticosteroids signifi-
cantly delay the onset of docetaxel-induced fluid retention: final
results of a randomized study of the European organization for
research and treatment of cancer investigational drug branch
for breast cancer,” Journal of Clinical Oncology, vol. 15, no. 9, pp.
3149–3155, 1997.
[25] R. K. Ramanathan, V. V. Reddy, J. M. Holbert, and C. P. Belani,
“Pulmonary infiltrates following administration of paclitaxel,”
Chest, vol. 110, no. 1, pp. 289–292, 1996.
[26] W. L. Read, J. E. Mortimer, and J. Picus, “Severe interstitial
pneumonitis associatedwith docetaxel administration,”Cancer,
vol. 94, no. 3, pp. 847–853, 2002.
[27] S. E. McGuire, A. M. Gonzalez-Angulo, E. H. Huang et al.,
“Postmastectomy radiation improves the outcome of patients
with locally advanced breast cancer who achieve a pathologic
complete response to neoadjuvant chemotherapy,” International
Journal of Radiation Oncology Biology Physics, vol. 68, no. 4, pp.
1004–1009, 2007.
[28] B. L. Fowble, J. P. Einck, D. N. Kim et al., “Role of postmas-
tectomy radiation after neoadjuvant chemotherapy in stage II-
III breast cancer,” International Journal of Radiation Oncology
Biology Physics, vol. 83, no. 2, pp. 494–503, 2012.
[29] J. L. Oh, M. J. Dryden, W. A. Woodward et al., “Locoregional
control of clinically diagnosed multifocal or multicentric breast
cancer after neoadjuvant chemotherapy and locoregional ther-
apy,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4971–4975,
2006.
[30] A. K. Garg, J. L. Oh, M. J. Oswald et al., “Effect of postmas-
tectomy radiotherapy in patients <35 years old with stage II-
III breast cancer treated with doxorubicin-based neoadjuvant
chemotherapy andmastectomy,” International Journal of Radia-
tion Oncology Biology Physics, vol. 69, no. 5, pp. 1478–1483, 2007.
[31] M. E. Straver, E. J. T. Rutgers, S. Rodenhuis et al., “The relevance
of breast cancer subtypes in the outcome of neoadjuvant
chemotherapy,” Annals of Surgical Oncology, vol. 17, no. 9, pp.
2411–2418, 2010.
[32] C. Liedtke, C. Mazouni, K. R. Hess et al., “Response to
neoadjuvant therapy and long-term survival in patients with
triple-negative breast cancer,” Journal of Clinical Oncology, vol.
26, no. 8, pp. 1275–1281, 2008.
[33] R. Bhargava, S. Beriwal, D. J. Dabbs et al., “Immunohisto-
chemical surrogate markers of breast cancer molecular classes
12 BioMed Research International
predicts response to neoadjuvant chemotherapy: a single insti-
tutional experience with 359 cases,” Cancer, vol. 116, no. 6, pp.
1431–1439, 2010.
[34] W. F. Symmans, F. Peintinger, C. Hatzis et al., “Measurement
of residual breast cancer burden to predict survival after
neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol.
25, no. 28, pp. 4414–4422, 2007.
[35] E. P. Mamounas, G. Tang, B. Fisher et al., “Association between
the 21-gene recurrence score assay and risk of locoregional
recurrence in node-negative, estrogen receptor-positive breast
cancer: results from NSABP B-14 and NSABP B-20,” Journal of
Clinical Oncology, vol. 28, no. 10, pp. 1677–1683, 2010.
[36] H. Nagar, E. A. Mittendorf, E. A. Strom et al., “Local-regional
recurrence with and without radiation therapy after neoadju-
vant chemotherapy and mastectomy for clinically staged T3N0
breast cancer,” International Journal of Radiation Oncology
Biology Physics, vol. 81, no. 3, pp. 782–787, 2011.
[37] T. A. Buchholz, C. D. Lehman, J. R. Harris et al., “Statement of
the science concerning locoregional treatments after preopera-
tive chemotherapy for breast cancer: a national cancer institute
conference,” Journal of Clinical Oncology, vol. 26, no. 5, pp. 791–
797, 2008.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
